Atossa Therapeutics, Inc. balance sheet

At the end of fiscal 2015, Atossa Therapeutics, Inc. had total assets of $6.2m, total liabilities of $2.5m and shareholders' equity of $3.7m. It held $3.7m in cash against $0 of debt: net cash of $3.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atossa Therapeutics, Inc.: balance sheet, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	LTMSept 2016
Cash and equivalents	2	2	6	9	4	4
Receivables	0	0	0	0	—	—
Inventory	—	0	0	0	0	—
Total current assets	3	2	7	9	4	5
Total assets	3	7	12	12	6	6
Accounts payable	0	0	0	1	1	0
Total current liabilities	2	2	1	2	3	1
Long-term debt	—	—	0	0	—	—
Total debt	1	0	0	0	0	0
Total liabilities	—	—	1	2	3	—
Shareholders' equity	2	5	11	9	4	5
Net debt (negative = net cash)	−1	−2	−6	−8	−4	−4
Shares outstanding	—	—	—	—	—	4m

US$ millions unless shown otherwise. Fiscal quarters.

Atossa Therapeutics, Inc.: balance sheet, quarterly
Quarter	2014 Q4Dec 2014	2015 Q1Mar 2015	2015 Q2Jun 2015	2015 Q3Sept 2015	2015 Q4Dec 2015	2016 Q1Mar 2016	2016 Q2Jun 2016	2016 Q3Sept 2016
Receivables	0	1	2	1	—	—	—	—
Inventory	0	0	0	0	0	—	—	—
Total current assets	9	11	14	10	4	3	1	5
Total assets	12	14	17	12	6	5	3	6
Accounts payable	1	1	1	1	1	0	0	0
Total current liabilities	2	3	3	3	3	1	1	1
Long-term debt	0	0	0	0	—	—	—	—
Total debt	0	0	0	0	—	—	—	—
Total liabilities	2	4	3	3	3	—	—	—
Shareholders' equity	9	10	13	9	4	4	2	5
Shares outstanding	25m	27m	29m	30m	2m	39m	40m	4m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atossa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atossa Therapeutics, Inc.